Tag Archives: Teva Pharmaceuticals

Feds charge Heritage execs with price fixing; DOJ ringing out 2016 on a roll against Pharma offenses

The former chief executive and former president of generic drug company Heritage Pharmaceuticals Inc. (Eatontown, NJ) have been charged with conspiring to fix prices, the first charges in a continuing… Read more »

Novartis slowly, quietly imploding; will Alcon, Amneal moves halt spiral?

Renewed whispers from Swiss drugmaker Novartis AG (Basel) that it could divest its struggling Alcon eyecare business reflect the latest step in dismantling former leader Dan Vasella’s vision of building… Read more »

Pharma stocks dive on price-fixing probes; better days for healthcare sector uncertain no matter who’s in the White House

The generic drug industry was jolted last week as shares of many major companies tumbled after a news report said that a federal inquiry into drug price-fixing was wider than… Read more »

Needing cash, Valeant in talks to sell stomach-drug unit in $10 billion deal; hedge-fund icon Bill Ackman finally has a good day

Valeant Pharmaceuticals International Inc. (Laval Quebec) is in advanced talks to sell a big stomach-drug business to Japan’s Takeda Pharmaceutical Co. for about $10 billion, a move seen easing pressure on Valeant over its… Read more »

Mylan Agrees to $465 Million EpiPen Settlement with US; But the Matter is Far From Over

Mylan NV (Amsterdam) will pay the US government $465 million in a swift settlement over how the drugmaker charged Medicaid for its allergy shot EpiPen, according to Bloomberg News. The… Read more »

Good News for Mylan after Hellish Week: Another Win in Patent War Over MS Drug; Lawyers on Both Sides Rejoice.

Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) had a third patent on its top-selling multiple sclerosis drug, Copaxone, invalidated last Thursday by a U.S. agency, a further blow to its… Read more »

Mylan Plans Generic EpiPen to Calm Pricing Outrage; Feels More Like a PR Move

Mylan NV’s latest attempt to deflect criticism over the price of allergy shot EpiPen failed to get the drugmaker out of the crosshairs of Congress this week. Last week, Chief… Read more »